Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
AI-matched digital twins for MYSTIC trial participants emulated the control arm and overall survival treatment effects.
'These findings highlight the potential for imaging-based digital twins to serve as robust external comparators in oncology clinical trials'— Dr. Omar Khan
MONTREAL, QUEBEC, CANADA, May 15, 2025 / EINPresswire.com / -- Altis Labs, Inc. ('Altis') will present findings at ISPOR 2025 demonstrating how real-world digital twins (rwDTs) can replicate control arm outcomes in AstraZeneca's randomized controlled Phase 3 MYSTIC trial in metastatic non-small cell lung cancer (mNSCLC). These results support the launch of Altis' new product offering that enables clinical development teams to generate external controls with AI applied to comprehensive real-world imaging + clinical + outcomes data.
Altis applied MYSTIC's eligibility criteria to its multimodal real-world data to identify historical patients treated with relevant standard-of-care (SOC) treatment. AI models processed the real-world baseline CT scans and quantified thousands of spatial imaging biomarkers representing total tumor burden, body composition, and other prognostic features. Using baseline imaging characteristics of each MYSTIC subject, 'matching' rwDTs were identified to generate an External Control Arms (ECAs).
AstraZeneca independently evaluated the survival outcomes of the ECAs and compared them to the MYSTIC trial arms, concluding that the ECAs successfully emulated the actual control arm and yielded consistent treatment effect estimates.
'CT Imaging – a 3D reconstruction of the entire patient anatomy – is the most comprehensive data modality already being used in clinical care and oncology trials,' said Felix Baldauf-Lenschen, CEO of Altis. 'It's no surprise that AI applied to this rich data alone can match patients' baseline characteristics to emulate efficacy readouts.'
'These findings highlight the potential for imaging-based digital twins to serve as robust external comparators in oncology clinical trials,' said the presenting author, Dr. Omar Khan, a Clinical Assistant Professor in the Cumming School of Medicine at the University of Calgary and Medical Oncologist at the Arthur J.E. Child Comprehensive Cancer Centre. 'This approach is particularly relevant to help enhance single-arm trials, where comparative evidence is often limited.'
Altis' ECA: A New Tool for Smarter Evidence Generation
The newly launched ECA product enables sponsors to generate external controls using their clinical trial imaging data and Altis' real-world imaging data + associated survival outcomes. Sponsors can use these ECAs in various ways:
• Benchmarking efficacy signal in single-arm trials
• Augmenting a control arm to increase statistical power in RCTs
• Real-world external comparators to inform reimbursement strategy
Altis' models are trained on a proprietary dataset of over 200,000 cancer patients with longitudinal imaging, demographic, diagnostic, treatment, and survival outcomes data, enabling robust matching.
The full results are featured at ISPOR 2025, Poster MSR147: Evaluating Imaging Artificial Intelligence (AI) Matching Real-World Digital Twins (rwDTs) Into an External Control Arm (ECA) for MYSTIC: A Phase 3 Clinical Trial in Metastatic Non-Small Cell Lung Cancer (mNSCLC).
About Altis Labs
Altis Labs is the computational imaging company accelerating clinical trials with AI. Altis has trained proprietary AI models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, and outcomes data. Top 20 biopharmas use Altis' AI models to more confidently analyze data from phase 1-4 clinical trials so that they can bring the most effective novel treatments to patients sooner.
For more information, visit www.altislabs.com, follow @AltisLabs on social media, or email [email protected].
Felix Baldauf-Lenschen
Altis Labs, Inc.
email us here
Visit us on social media:
LinkedIn
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Pharmaceutical company AstraZeneca sues Utah Attorney General over discount medication law
SALT LAKE CITY () — The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah Insurance Commissioner Jon Pike over a recent law that is intended to allow more pharmacies to have access to drug discount programs. In a lawsuit filed May 23, AstraZeneca alleges that Utah SB 69 is unconstitutional. The law was introduced and passed in the 2025 General Assembly, and it went into effect on May 7. The law prohibits drug manufacturers from restricting pharmacies from working with 340B entities, which help pharmacies and patients access medications at a discounted price. Senator Lee responds to the Trump-Musk feud The 340B Drug Pricing Program is a that 'enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services,' according to the Health Resources and Services Administration (HRSA) website. It means that drug manufacturers participating in Medicaid agree to provide 'outpatient drugs to covered entities at significantly reduced prices.' All organizations need to be registered and enrolled in the 340B program in order to purchase discounted medications. The law that established the 340B Program, Section 340B(a)(4) of the Public Health Service Act, specified certain types of for the program, such as medical centers that serve rural and other underserved communities and clinics that specialize in particular diseases like HIV/AIDS. SB 69 expands the scope, requiring drug manufacturers to provide the discounts to third-party pharmacies that are contracting with 340B entities, and this is what AstraZeneca is claiming is unconstitutional in its lawsuit. Utah House Republicans elect new leadership members The lawsuit states that because price controls 'disincentivize innovation and destabilize markets,' Congress chose to specifically limit the types of organizations that are eligible in Section 340B. The suit notes that for-profit pharmacies like Walgreens or CVS were not included as eligible, and there have already been several federal court cases ruling that block efforts to require drug manufacturers to provide discounts to contracted pharmacies. AstraZeneca claims in its suit that SB 69 'requires pharmaceutical manufacturers to offer 340B-discounted pricing for sales at an unlimited number of contract pharmacies,' expanding 340B discounts to 'an entirely new category of transactions not covered by Section 340B itself.' The suit alleges that SB 69 directly conflicts with federal law requirements, and therefore, it cannot be enforced against Astrazeneca or other drug manufacturers. AstraZeneca is asking the court to declare SB 69 unconstitutional and to order that Utah AG Derek Brown and Insurance Commissioner Jon Pike not enforce the law against AstraZeneca. Musk floats 'The American Party' after Trump tiff Myths VS Facts: What health officials want you to know about the MMR vaccine Good4Utah Road Tour: Willard Bay State Park Lori Vallow Daybell back in court, charged with conspiracy to murder ex nephew-in-law Man charged with assault for allegedly attacking and strangling neighbor Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
AstraZeneca sues Utah attorney general over new drug pricing law
AstraZeneca, a major pharmaceutical company, has sued Utah's Attorney General Derek Brown over a recently passed state law allowing for lower pricing in pharmacies. The lawsuit concerns how SB69, passed during the 2025 state legislative session, deals with Section 340B of the federal Public Health Service Act. The suit was filed in May in the U.S. District Court of the District of Utah. The lawsuit argues that SB69 violates federal law by expanding the 340B drug discount program to unlimited pharmacies. The 340B drug discount program is designed to provide pricing benefits to specific eligible health care entities. It requires pharmaceutical manufacturers to offer products at steeply discounted rates for a specific list of entities. 'Because such price controls can disincentivize innovation and destabilize markets, Congress carefully crafted Section 340B and limited participation in the program to fifteen — and only fifteen — types of covered entities," per the lawsuit. It also points out that for-profit pharmacy chains, such as CVS and Walgreens, were not included in the list of covered entities. AstraZeneca's suit seeks for an order declaring that SB69 violates federal law and is unconstitutional. It also seeks to stop Brown and Utah Insurance Commissioner Jon Pike from enforcing SB69 against AstraZeneca in any manner. The Utah Attorney General's Office said Friday it had no comment on the lawsuit. SB69, which was sponsored by Sen. Evan Vickers, R-Cedar City, defines terms related to the 340B drug discount program and prohibits pharmaceutical manufacturers from setting certain restrictions. Under the law, manufacturers cannot prohibit or restrict pharmacies from contracting with 340B entities. They also cannot deny these 340B entities access to specific drugs. 'Apparently dissatisfied with the scope of federal law, the State of Utah has enacted a statute seeking to achieve under state law precisely the same result that federal courts have resoundingly rejected,' per the suit. 'The state law requires pharmaceutical manufacturers to offer 340B-discounted pricing for sales at an unlimited number of contract pharmacies.' The suit says that SB69 extends Section 340B price caps beyond the scope of the federal program, requiring manufacturers to make discounted drugs available for sale at any and all pharmacies 'authorized by a 340B entity to receive the drug.' It alleges that the law extends the discounts to new categories of transactions that are not covered by the program, thus conflicting with federal law requirements. The suit argues that the law conflicts with federal law, specifically court rulings that 'make clear that the federal 340B statute does not obligate manufacturers to deliver discounted drugs to unlimited contract pharmacies." According to the suit, SB69 also violates federal patent law, which 'prohibits states from regulating the price of patented goods.' 'It requires manufacturers like AstraZeneca to offer steeply discounted prices for the sale of their patented drugs, thereby extending federal price caps to an additional category of patented drug sales (contract pharmacy sales) that federal courts have held fall outside of the 340B program. It also argues that SB69 violates the Contracts Clause of the U.S. Constitution and the Constitution's takings clause.
Yahoo
a day ago
- Yahoo
ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers
Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed every year and 200,000 deaths occurring. With such a high healthcare burden, rapid advancements have been made with the advent of programmed cell death protein-1 checkpoint inhibition and immunotherapy, although they have only been proven successful in the first-line paradigm. Unlike non-small cell lung cancer (NSCLC), the treatment options for SCLC are more limited, as it is more aggressive and develops resistance to available treatments rapidly. One of the current standards of care (SOC) is the use of platinum-based chemotherapy such as cisplatin in combination with Roche's Tecentriq or AstraZeneca's Imfinzi in the first-line treatment for extensive-stage SCLC (ES-SCLC). Following treatment, many patients with NSCLC will develop platinum resistance through strengthened DNA-repair capabilities and reduced chemotherapy uptake in the cancerous cells. Amgen's Imdelltra, a bispecific T-cell engager (BiTE) that targets Delta-like canonical Notch ligand 3 (DLL3) and cluster of differentiation 3 (CD3) receptors, received US Food and Drug Administration approval for the treatment of patients with ES-SCLC following disease progression or following platinum-based chemotherapy, based on results from the DeLLphi-301 trial. While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted as DeLLphi-301 was a Phase II trial with only one arm and no comparator. Results from the American Society of Clinical Oncology 2025 have shown the latest in Imdelltra's clinical results from the DeLLphi-304 trial. DeLLphi-304 enrolled 254 patients receiving Imdelltra and 255 receiving one of the following: topotecan, amrubicin, or Jazz Pharmaceutical's Zepzelca. Zepzelca and topotecan are preferred systemic treatment options for SCLC. Imdelltra was found to increase overall survival by 5.3 months (hazard ratio: 0.60, P<0.001) and increase median progression-free survival. There was also a large difference in grade 3 treatment-related adverse events, with Imdelltra reducing the rate by 35% compared to the control arm. Absent any competing immunotherapies with a preferred National Comprehensive Cancer Network opinion, Imdelltra is expected to be an attractive option for many patients looking to enhance their care. The annual cost of Imdelltra therapy totals $167,600 per patient. As a result, Imdelltra will likely struggle to receive reimbursement outside of the US. Despite the high cost, the clinical benefits are clear and Imdelltra's US market share uptake will be enhanced with these positive results, particularly owing to its more manageable safety profile when compared to existing options for this segment. Leading data and analytics company GlobalData's indication-based forecast shows Imdelltra will reach $1.76bn globally by 2031. "ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
